Financial GuidanceHRTX shares reacted positively due to the strength of the top-line and the increase in 2025 adjusted EBITDA guidance range.
Product PerformanceZynrelef's differentiated profile, offering 72-hour pain relief and opioid-sparing outcomes, positions it as a potential product of choice in the post-surgical pain market.
ProfitabilityCinvanti recovery and strong Zynrelef performance allowed the company to achieve profitability with non-GAAP net income of $3.6MM.